What's new? Log in Free sign up

OS Therapies (OSTX)

Company Profile

Company profile

Ticker

OSTX

Exchange

Website

ostherapies.com

CEO

Mr. Paul A. Romness M.P.H.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

OS THERAPIES Inc

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

825118368

OSTX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$17.50

Low target

$15.00

High target

$20.00

D. Boral Capital

Latest filings (excl ownership)

View all

IPO registration

31 Jan 25

Entry into a Material Definitive Agreement

$10.00 mm in equity / options / securities to be acquired, sold $7.10 mm, 34 investors

Entry into a Material Definitive Agreement

Notice of effectiveness

Registration of securities for employees

IPO registration (amended)

3 Jan 25

OS Therapies Announces Closing of $6 Million Private Placement

OS Therapies Announces Pricing of $6 Million Private Placement

Latest ownership filings

View all

Shalom Auerbach

Shalom Auerbach

Shalom Auerbach

Olivier Roger Jarry

Avril Suzette McKean-Dieser

SATTERFIELD THOMAS A JR

Theodore F. Search

Theodore F. Search

Paul A. Romness

Financial summary

Financial statements Chart OSTX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)	1.86 mm		1.86 mm
Cash burn (monthly)	(no burn)		812.46 k
Cash used (since last report)	n/a		3.34 mm
Cash remaining	n/a		-1.48 mm
Runway (months of cash)	n/a		-1.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

OSTX institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	0	NEW
Opened positions	1	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	280.00 k	0.00	NEW
Total shares	100.00	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Armstrong Advisory	100.00	$280.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Armstrong Advisory	100.00	+100.00	NEW
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

OSTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jan 25	Shalom Auerbach	Common Stock, par value $0.001 per share	Sell	Dispose S	Yes	No	6.735	16,720	112.61 k	2,531,211
2 Aug 24	John Ciccio	Common Stock	Conversion	Acquire C	Yes	No	0	30,264	0.00	435,835
2 Aug 24	John Ciccio	Common Stock	Conversion	Acquire C	Yes	No	0	266,306	0.00	405,571
2 Aug 24	John Ciccio	Common stock, par value $0.001 per share ("Common Stock")	Conversion	Acquire C	Yes	No	0	101,765	0.00	139,265
2 Aug 24	Theodore F. Search	Common Stock	Conversion	Acquire C	Yes	No	0	30,264	0.00	435,835
2 Aug 24	Theodore F. Search	Common Stock	Conversion	Acquire C	Yes	No	0	266,306	0.00	405,571
2 Aug 24	Theodore F. Search	Common stock, par value $0.001 per share ("Common Stock")	Conversion	Acquire C	Yes	No	0	101,765	0.00	139,265

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.

Maxim Group Maintains Buy on OS Therapies, Raises Price Target to $15

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Press releases

From Benzinga Pro

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical control

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

CEO Paul Romness available to meet with institutional investors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment,

OS Therapies Announces Closing of $6 Million Private Placement

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.